About Eledon Pharmaceuticals Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://eledon.com/
Frequently Asked Questions
What is the 52-week range for ELDN?
The 52-week high is $4.6 and the 52-week low is $1.35.
What is the P/E ratio for ELDN?
The P/E ratio data is currently unavailable.
What is the dividend yield for ELDN?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -98.48%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 0.83.
Analyst Recommendation Trends
Wall Street analyst consensus for ELDN over the last few months:
Latest ELDN News
Eledon Pharmaceuticals, Inc. (ELDN) Presents at International Congress of The Transplantation Society 2026 - Slideshow
2026-09-22. The following slide deck was published by Eledon Pharmaceuticals, Inc.
Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society
Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an approximately 13 mL/min/1.73 m² advantage versus tacrolimus (71 vs. 58 mL/min/1.73 m²) at month 24 No rejections occurred in the tegoprubart arm beyond six months post-transplant, compared with seven in the tacrolimus arm Tegoprubart granted U.S. FDA Fast Track designation for the prevention of rejection in kidney transplantation Phase 3 LEGACY study expe
Eledon Presents Updated Long-Term Data From Phase 2 BESTOW Clinical Program Evaluating Tegoprubart In Patients Undergoing Kidney Transplantation At International Congress Of The Transplantation Society
Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an approximately 13 mL/min/1.73 m² advantage versus tacrolimus (71 vs. 58
Eledon Pharmaceuticals Says FDA Grants Fast Track Designation To Tegoprubart For Prevention Of Rejection In Kidney Transplantation; Expects To Initiate Phase 3 LEGACY Study In Q4 2026
Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an approximately 13 mL/min/1.73 m² advantage versus tacrolimus (71 vs. 58
Eledon Pharmaceuticals Announces Presentation at the International Congress of The Transplantation Society
IRVINE, Calif., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced an oral presentation highlighting the long-term safety and efficacy of tegoprubart in preventing kidney transplant rejection will take place at the upcoming International Congress of The Transplantation Society in Sydney, Australia, from September 20–23, 2026. Details of the presentation are below: Oral Presentation Title: Phase 2 BESTOW trial and the BESTOW EXTENSION: Evalua
Eledon Pharmaceuticals Announces Islet Cell Transplantation IND Submission, First Patients Enrolled in Multiple Transplant Programs, and Reaffirms Plan to Initiate Phase 3 Kidney Transplantation Trial in Fourth Quarter 2026
IND submitted to FDA for Eledon-sponsored, registrational study of tegoprubart in islet cell transplantation for patients with type 1 diabetes First patients enrolled in new investigator-initiated study of tegoprubart in patients with renal dysfunction receiving an islet cell transplant First patient dosed under compassionate use of tegoprubart for conversion from tacrolimus in islet cell transplant recipients with calcineurin inhibitor related kidney dysfunction First patients dosed under compa
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-07-31 | Gros David-Alexandre C | -194,791 | $3.38 | $658,394 |
| 2026-07-31 | Gros David-Alexandre C | +354,454 | - | - |
| 2026-07-31 | Perrin Steven | -72,138 | $3.38 | $243,826 |
| 2026-07-31 | Perrin Steven | +152,353 | - | - |
| 2026-01-10 | McBride John S. | -3,430 | - | - |
| 2026-01-10 | McBride John S. | +3,430 | - | - |
| 2026-01-10 | Hillson Jan | -3,430 | - | - |
| 2026-01-10 | Hillson Jan | +3,430 | - | - |
| 2026-01-10 | Kirk Allan | -3,430 | - | - |
| 2026-01-10 | Kirk Allan | +3,430 | - | - |
| 2026-01-10 | Lee June | -3,430 | - | - |
| 2026-01-10 | Lee June | +3,430 | - | - |
| 2026-01-10 | Robinson James A. Jr. | -3,430 | - | - |
| 2026-01-10 | Robinson James A. Jr. | +3,430 | - | - |
| 2026-01-10 | Katkin Keith | -8,575 | - | - |
| 2026-01-10 | Katkin Keith | +8,575 | - | - |